BTIG raised the firm’s price target on RxSight to $43 from $36 and keeps a Buy rating on the shares as part of a broader research note on Medical Technology. The company continues to take share and grow the market in the premium IOL segment, the analyst tells investors in a research note. 2024 is also an election year which usually does see some slightly better performance for MedTech vs. the S&P before rallying post-election, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RXST:
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades RxSight to Overweight, raises price target to $42
- Wells Fargo gets more bullish on RxSight, upgrades shares
- RxSight initiated with bullish view at Stifel, here’s why
- RxSight price target raised by $5 at Needham, here’s why
